Ragweed Allergy - Pipeline Review, H2 2016

  • ID: 3804683
  • Report
  • 37 pages
  • Global Markets Direct
1 of 6
Ragweed Allergy - Pipeline Review, H2 2016

Summary

‘Ragweed Allergy - Pipeline Review, H2 2016’, provides an overview of the Ragweed Allergy pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Ragweed Allergy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Ragweed Allergy and features dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Ragweed Allergy
- The report reviews pipeline therapeutics for Ragweed Allergy by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Ragweed Allergy therapeutics and enlists all their major and minor projects
- The report assesses Ragweed Allergy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Ragweed Allergy

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Ragweed Allergy
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Ragweed Allergy pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
READ MORE
Note: Product cover images may vary from those shown
2 of 6
List of Tables

List of Figures

Introduction

Report Coverage

Ragweed Allergy Overview

Therapeutics Development

Pipeline Products for Ragweed Allergy - Overview

Ragweed Allergy - Therapeutics under Development by Companies

Ragweed Allergy - Pipeline Products Glance

Clinical Stage Products

Early Stage Products

Unknown Stage Products

Ragweed Allergy - Products under Development by Companies

Ragweed Allergy - Companies Involved in Therapeutics Development

Anergis SA

Biomay AG

Circassia Pharmaceuticals Plc

Immunomic Therapeutics, Inc.

Ragweed Allergy - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Target

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

AllerR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BM-34 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Multi-LAMP-Vax - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PL-101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine for Asthma and Ragweed-Induced Rhinoconjunctivitis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Ragweed Allergy - Dormant Projects

Ragweed Allergy - Discontinued Products

Ragweed Allergy - Product Development Milestones

Featured News & Press Releases

Dec 19, 2014: Anergis Granted U.S. Patent for Ragweed Allergy Vaccine AllerR

Dec 08, 2014: Circassia Announces Top-Line Results from Ragweed Allergy Treatment Phase IIb Chamber Study

Feb 21, 2013: Anergis To Present Preclinical Data On Ragweed Allergy Vaccine Candidate AllerR At AAAAI 2013 Annual Meeting

Jun 14, 2012: Anergis Reaches Several Preclinical Development Milestones With Ragweed Pollen Vaccine

Mar 07, 2012: Circassia’s Ragweed Allergy Therapy Achieves Positive Phase II Clinical Results

Jan 19, 2012: Circassia Receives European Patent For Its Ragweed Allergy T-Cell Vaccine

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer 37List of Tables

Number of Products under Development for Ragweed Allergy, H2 2016

Number of Products under Development by Companies, H2 2016

Comparative Analysis by Clinical Stage Development, H2 2016

Comparative Analysis by Early Stage Development, H2 2016

Comparative Analysis by Unknown Stage Development, H2 2016

Products under Development by Companies, H2 2016

Ragweed Allergy - Pipeline by Anergis SA, H2 2016

Ragweed Allergy - Pipeline by Biomay AG, H2 2016

Ragweed Allergy - Pipeline by Circassia Pharmaceuticals Plc, H2 2016

Ragweed Allergy - Pipeline by Immunomic Therapeutics, Inc., H2 2016

Assessment by Monotherapy Products, H2 2016

Number of Products by Stage and Target, H2 2016

Number of Products by Stage and Route of Administration, H2 2016

Number of Products by Stage and Molecule Type, H2 2016

Ragweed Allergy - Dormant Projects, H2 2016

Ragweed Allergy - Discontinued Products, H2 2016 31List of Figures

Number of Products under Development for Ragweed Allergy, H2 2016

Number of Products under Development by Companies, H2 2016

Assessment by Monotherapy Products, H2 2016

Number of Products by Routes of Administration, H2 2016

Number of Products by Stage and Routes of Administration, H2 2016

Number of Products by Molecule Types, H2 2016

Number of Products by Stage and Molecule Types, H2 2016
Note: Product cover images may vary from those shown
3 of 6

Loading
LOADING...

4 of 6
Ragweed Allergy pipeline therapeutics constitutes close to 5 molecules. which approximately 5 molecules are developed by Companies.Our latest report Ragweed Allergy – Pipeline Review, H2 2016, outlays comprehensive information on the therapeutics under development for Ragweed Allergy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

Ragweed Allergy Ragweed allergy occurs when ragweed pollen in the air enters the nose and throat of people who are allergic to that pollen, it can cause allergy and asthma symptoms. Symptoms include sneezing, runny or stuffy nose, itchy throat or inside of ears, hives, and swollen eyelids and itchy eyes. Treatment includes decongestant, antihistamine and nasal corticosteroid. The molecules developed by Companies in Phase II, Preclinical and Unknown stages are 1, 3 and 1 respectively.

Furthermore, this report also reviews of key players involved in therapeutic development for Ragweed Allergy and features dormant and discontinued projects. Driven by data built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Product cover images may vary from those shown
5 of 6
Anergis SA
Biomay AG
Circassia Pharmaceuticals Plc
Immunomic Therapeutics, Inc.
Note: Product cover images may vary from those shown
6 of 6
Note: Product cover images may vary from those shown
Adroll
adroll